)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Tonix Pharmaceuticals
Tonix Pharmaceuticals (TNXP) investor relations material
Tonix Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Achieved FDA approval and commercial launch of TONMYA for fibromyalgia, the first new medicine for this indication in over 15 years, with over 4,200 prescriptions since launch in November 2025.
Advanced clinical pipeline with IND clearance for TNX-102 SL in major depressive disorder and in-licensed TNX-4800 for Lyme disease prevention.
Strengthened financial position with $207.6 million in cash and cash equivalents at year-end 2025 and completed a $20 million direct offering.
Financial highlights
Full year 2025 net product revenue was $13.1 million, up from $10.1 million in 2024; Q4 2025 revenue was $5.4 million, up from $2.6 million in Q4 2024.
Net loss for 2025 was $124.0 million ($14.57 per share), compared to $130.0 million ($176.60 per share) in 2024.
Research and development expenses rose to $44.5 million in 2025 from $40.0 million in 2024; selling, general, and administrative expenses increased to $87.7 million from $40.1 million.
Cash used in operations was $99.8 million for 2025, up from $60.9 million in 2024.
Outlook and guidance
Plans to initiate U.S. field study for TNX-4800 in 2027, pending FDA clearance.
Enrollment for Phase 2 HORIZON study of TNX-102 SL in major depressive disorder expected to begin mid-2026.
Cash resources expected to fund operations into Q1 2027.
Impact of bridge prescriptions on TONMYA revenue
FDA feedback on TNX-4800 human challenge study
TNX-1500 Phase 2 trial in kidney transplantation
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tonix Pharmaceuticals
- New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline.TNXP
Life Sciences Virtual Investor Forum11 Mar 2026 - Tonmya launches as the first new fibromyalgia drug in 15 years, driving growth and pipeline momentum.TNXPInvestor presentation11 Mar 2026
- Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones.TNXPTD Cowen 46th Annual Health Care Conference4 Mar 2026
- FDA decision for TNX-102SL in fibromyalgia expected August 2025, with strong pipeline progress.TNXPLife Sciences Virtual Investor Conference26 Dec 2025
- Shelf registration allows up to $500M in flexible offerings to fund a diverse biotech pipeline.TNXPRegistration Filing16 Dec 2025
- Biopharma firm registers $300M shelf for pipeline and working capital amid substantial risk factors.TNXPRegistration Filing16 Dec 2025
- Amended filing updates an exhibit; auditor flags going concern risk.TNXPRegistration Filing16 Dec 2025
- Annual meeting seeks approval for director elections, reverse split, and compensation plans.TNXPProxy Filing2 Dec 2025
- Annual meeting covers director elections, stock split, equity plans, and executive pay votes.TNXPProxy Filing2 Dec 2025
Tonix Pharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, rare diseases, and infectious diseases. The company’s pipeline includes treatments for conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, and long COVID. Tonix Pharmaceuticals also explores vaccine and antiviral drug candidates for infectious disease prevention and treatment. The company is headquartered in Chatham, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage